- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
Hb0025 is a bispecific antibody that targets PD-L1 and vascular endothelial growth factor (VEGF), with EC50 values of 0.67 nM and 0.48 nM, respectively. It exerts anti-tumor effects by inhibiting VEGF activity and promoting T-cell infiltration into tumors, thereby transforming the immunosuppressive tumor microenvironment into an immune-activated state. MW: 170.8 KD.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Name | Citation | PD-1/PD-L1 interaction | PD-1 | PD-L1 | PD-1/PD-L1 | Others |
|---|---|---|---|---|---|---|
| GS-4224 | 0 | |||||
| INCB086550 | 1 | |||||
| BMS-1001 | 0 | |||||
| BMS-1166 | 8 | |||||
| PD-1/PD-L1 Inhibitor 3 | 13 | |||||
| BMS-1 | 13 | |||||
| BMS202 | 26 | |||||
| CA-170 (AUPM-170) | 0 | |||||
| SR 0987 | 1 | IL17,RORγt | ||||
| Spartalizumab (anti-PD-1) | 3 | |||||
| Camrelizumab (anti-PD-1) | 2 | |||||
| AUNP-12 | 3 |
| Description |
Hb0025 is a bispecific antibody that targets PD-L1 and vascular endothelial growth factor (VEGF), with EC50 values of 0.67 nM and 0.48 nM, respectively. It exerts anti-tumor effects by inhibiting VEGF activity and promoting T-cell infiltration into tumors, thereby transforming the immunosuppressive tumor microenvironment into an immune-activated state. MW: 170.8 KD.
|
|---|
| CAS No. | N/A |
|---|---|
| Source | CHO |
| Storage (From the date of receipt) |
-80℃(avoid freeze-thaw cycles) |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.